Citi Says AstraZeneca Rare-Disease Drug Data Supports Sales Potential

Citi analysts say data on experimental efzimfotase alfa supports potential use beyond children and the drug’s sales prospects. AstraZeneca has filed for U.S. approval to treat a rare condition.